Epcore Fl-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Lorenzo Falchi; Franck Morschhauser; Kim Linton; Huiqiang Huang; Faith Galderisi; Syed Quadri; Lingmin Zeng; Daniela Hoehn; John F. Seymour

doi:10.1182/blood-2023-180092

Epcore Fl-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Lorenzo Falchi, Franck Morschhauser, Kim Linton, Huiqiang Huang, Faith Galderisi, Syed Quadri, Lingmin Zeng, Daniela Hoehn, John F. Seymour

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	4
Journal	Blood
Volume	142
DOIs	https://doi.org/10.1182/blood-2023-180092
Publication status	Published - 2 Nov 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2023-180092

Cite this

@article{c7cd4dff7b294602838a342e4248eea0,

title = "Epcore Fl-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma",

author = "Lorenzo Falchi and Franck Morschhauser and Kim Linton and Huiqiang Huang and Faith Galderisi and Syed Quadri and Lingmin Zeng and Daniela Hoehn and Seymour, {John F.}",

year = "2023",

month = nov,

day = "2",

doi = "10.1182/blood-2023-180092",

language = "English",

volume = "142",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Epcore Fl-1

T2 - Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

AU - Falchi, Lorenzo

AU - Morschhauser, Franck

AU - Linton, Kim

AU - Huang, Huiqiang

AU - Galderisi, Faith

AU - Quadri, Syed

AU - Zeng, Lingmin

AU - Hoehn, Daniela

AU - Seymour, John F.

PY - 2023/11/2

Y1 - 2023/11/2

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001159740302162&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1182/blood-2023-180092

DO - 10.1182/blood-2023-180092

M3 - Meeting Abstract

SN - 0006-4971

VL - 142

JO - Blood

JF - Blood

ER -

Epcore Fl-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

UN SDGs

Access to Document

Other files and links

Cite this